ATLANTA, Jan. 9, 2013 /PRNewswire/ -- Jay S. Yadav, MD, CEO and founder of CardioMEMS, has been named a recipient of the Industry Growth Award, the highest honor bestowed each year by Georgia Bio for extraordinary contributions to the growth of Georgia's life sciences industry.
Dr. Yadav was recognized for his success as an entrepreneur and leader of Georgia's bioscience community, as well as his leadership at CardioMEMS', pioneering work in developing and marketing wireless sensing and communication technology for the human body. CardioMEMS' technology platform is designed to improve the management of severe chronic cardiovascular diseases such as aneurysms, heart failure, and hypertension.
Also recognized with an Industry Growth Award from the public sector is Chris Cummiskey, Commissioner of the Georgia Department of Economic Development. The awards will be presented January 24, 2013, at Atlanta's historic Fox Theatre during Georgia Bio's annual awards ceremony and fundraiser for educational programming initiatives.
"Our Industry Growth Award recognizes leaders in the public and private sectors whose accomplishments highlight the innovation and passion required to transform healthcare," said Thomas Callaway, MD, MBA, Chairman of Georgia Bio, and Founder and President of Life Science Partner, Inc. "CardioMEMS' breakthrough monitoring technology gives physicians and patients physiological data that can improve outcomes and save lives. The company's continued success is a tribute to Dr. Yadav's outstanding leadership."
Learn more about the Georgia Bio awards at www.gabio.org/awards
About Georgia Bio
Georgia Bio (www.gabio.org) is the private, non-profit association whose members include pharmaceutical, biotechnology and medical device companies, medical centers, universities and research institutes, government groups and other business organizations involved in the development of life sciences related products and services.
For more information, visit www.gabio.org.
About CardioMEMS, Inc.
CardioMEMS is a medical device company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body. The Company's technology platform is designed to improve the management of severe chronic cardiovascular diseases such as aneurysms, heart failure and hypertension. CardioMEMS miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data, which are critical to the management of patients. The sensors are designed to be permanently implanted into the heart and blood vessels due to their small size, durability and lack of wires and batteries. Using radiofrequency energy, the sensors transmit real-time data to external electronic readers, which then communicate this information to the patient's physician. The Company developed this technology based on the belief that frequent, on-demand, real-time monitoring of vital information enables proactive patient management, which holds the promise of reducing hospitalizations, improving a patient's quality of life and delivering more efficient and cost effective health care. More information about the CardioMEMS is located at www.cardiomems.com.
Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company's products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.
CardioMEMS, Champion and the CardioMEMS logo are registered trademarks of CardioMEMS, Inc.
Caution: The Champion Heart Failure Monitoring System is an investigational device limited by federal law to investigational use.
SOURCE CardioMEMS, Inc.